This shouldn’t be any shocker now, but the small-cap biotech stocks are getting attention this morning. Of particular interest are the ones with clinical development programs for prostate and other cancers. When you get a stock like Dendreon (DNDN) with such a massive short interest and with such a large open interest in the options that just happens.
Here is a small sample of some pre-market biotech movers:
Dendreon (DNDN) is up 250% or so…….
Cell Genesys (CEGE) up 32% to $4.65 (similar drug under development)
Biomira (BIOM) up 21% to $1.28
Introgen (INGN) up 14% at $4.43
Genitope (GTOP) up 12% at $4.16
Geron (GERN) up 3% at $7.20
StemCell (STEM) up 3% at $2.62
Introgen (INGN) up 11% at $4.32
Medarex (MEDX) up 7% at $12.20 (see last week options notes)
Cytogen (CYTO) up 7% to $2.25
This is the sort of news that may even get some of the old deadbiotech zombies going, so don’t be shocked when you see some mysterystock moves up and down today.
Jon C. Ogg
March 30, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Top Gaining Stocks
Top Losing Stocks